Strong Bioprocessing Performance
Bioprocessing business showed strong growth with low double-digit growth in consumables and high single-digit growth in the biotechnology segment.
Free Cash Flow and Earnings Growth
Generated $1.1 billion of free cash flow in the quarter, with adjusted diluted net earnings per share up approximately 5% year-over-year.
New Product Launches and Innovations
Significant investments in new products like Syteva's protein A resins and XenoTOS 8600 mass spectrometry, enhancing long-term competitive positioning.
Resilience in Diagnostics
Diagnostics segment showed core revenue increase of 2%, with Cepheid's non-respiratory revenue growing double digits.
CFO Succession Plan
Announced CFO succession with Matt Gugino taking over, ensuring continuity and leadership strength.